The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCambridge Cog Regulatory News (COG)

Share Price Information for Cambridge Cog (COG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 48.50
Bid: 48.00
Ask: 49.00
Change: 0.00 (0.00%)
Spread: 1.00 (2.083%)
Open: 48.50
High: 48.50
Low: 48.50
Prev. Close: 48.50
COG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

£1.1 million eCOA contract win

19 Oct 2022 07:00

RNS Number : 3270D
Cambridge Cognition Holdings PLC
19 October 2022
 

 

Cambridge Cognition Holdings Plc

("Cambridge Cognition" or the "Company")

 

£1.1 million eCOA contract win for rare blood disease trial

 

Cambridge Cognition Holdings Plc (AIM: COG), which develops and markets digital solutions to assess brain health, is pleased to announce that it has won a £1.1m contract with a major pharmaceutical company to provide electronic clinical outcome assessments ("eCOA") and hardware for a rare blood disease study running over the next two years. The new contract, with an existing customer, is for a mixture of eCOA licenses, services and hardware to support an upcoming clinical trial.

 

As a leader in digital outcome assessments, Cambridge Cognition primarily provides cognitive measures and eCOA solutions for clinical trials in central nervous systems disorders. Impressed by Cambridge Cognition's expertise and performance in handling multi-site-multi-language studies, the customer has selected the Company to be the eCOA provider for this trial. This recognition is important for the Company as the provision of eCOA for clinical trials is a sizeable growth market, valued at over US$1bn per annum and growing at more than 15% according to market research1. 

 

Cambridge Cognition has been contracted to provide the platform and the hardware for capturing participants' experiences as well as their responses to standardised questionnaires and scales. Cambridge Cognition's experienced clinical project management team will work closely with the customer to ensure successful use of the software and devices. 

 

Commenting, Matthew Stork, Chief Executive Officer of Cambridge Cognition, said: 

"Cambridge Cognition has a strong history of delivering cognitive assessments in the field, traditionally in clinics and now also at home. We are pleased to see this new order from an existing client, our reputation for quality, service and scientific rigour is enabling us to win eCOA-only clinical trials."

 

References

1. GrandView Research 2018 eCOA Report

 

For further information, contact:

 

Cambridge Cognition Holdings Plc

Matthew Stork, Chief Executive Officer

Stephen Symonds, Chief Financial Officer

Tel: 012 2381 0700

press@camcog.com

Panmure Gordon (UK) Limited (NOMAD and Joint Broker)

Freddy Crossley / Emma Earl

Rupert Dearden

Tel: 020 7886 2500

(Corporate Finance)

(Corporate Broking)

Dowgate Capital Limited (Joint Broker)

David Poutney / James Serjeant

Tel: 020 3903 7715

 

IFC Advisory Ltd (Financial PR and IR)

Tim Metcalfe / Graham Herring / Zach Cohen

Tel: 020 3934 6630

 

 

The information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014.

 

Notes to Editors

 

About Cambridge Cognition

 

Cambridge Cognition is a technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The Company's software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.

 

For further information visit www.cambridgecognition.com

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
CNTEAXEPFLKAFFA
Date   Source Headline
16th Mar 20167:00 amRNSTrading Update
1st Mar 20167:00 amRNSWearables partnership
15th Feb 20167:00 amRNSDirectorate Change
8th Dec 20157:00 amRNSNew medical device
20th Nov 20157:00 amRNSYear End Trading Update
8th Oct 20157:00 amRNSTwo software licence agreements
21st Sep 20157:00 amRNSFormation of Cantab Corporate Health Limited
10th Sep 20157:00 amRNSHalf Yearly Report
9th Sep 20157:00 amRNSNew patent application
20th Aug 20157:00 amRNSNotice of Results
22nd Jul 20152:30 pmRNSNew research delivered at AAIC
9th Jul 201512:08 pmRNSDirector dealing and Grant of Options
8th Jul 20155:15 pmRNSRe: Directorate Change
1st Jul 201512:00 pmRNSAppointment of Chief Operating Officer
8th Jun 20158:53 amRNSDirector dealing
2nd Jun 201510:30 amRNSAppointment of Non-Executive Director
27th May 201510:33 amRNSResult of AGM
27th May 20157:00 amRNSAGM Statement
21st May 20153:17 pmRNSIssue of Equity
20th May 20157:00 amRNSNew cognitive assessment product
12th May 20157:01 amRNSInvestor teach-in
6th May 20159:35 amRNSHolding(s) in Company
6th May 20157:02 amRNSNew Applications in Healthcare
1st May 201512:02 pmRNSPosting of Annual Report & Notice of AGM
14th Apr 20157:00 amRNSSales of Cantab Connect iPad product exceed £1m
12th Mar 20157:00 amRNSFinal Results
4th Mar 20157:00 amRNSUS office opened
3rd Mar 20157:00 amRNSNotice of Results
21st Jan 20157:00 amRNSLaunch of new iPad research product
16th Dec 20143:12 pmRNSHolding(s) in Company
15th Dec 20149:21 amRNSDirector/PDMR Shareholding
21st Nov 20145:13 pmRNSDirector Declaration
30th Oct 20147:00 amRNSSupporting the Dementias Research Platform UK
23rd Oct 20147:00 amRNSLaunch of CTIS-Profile 2+ on Cantab Connect
1st Oct 20147:00 amRNSDirector/PDMR Shareholding
29th Sep 201412:40 pmRNSReplacement - Director/PDMR Shareholding
29th Sep 201410:06 amRNSDirector/PDMR Shareholding
24th Sep 201410:22 amRNSHolding(s) in Company
24th Sep 20147:00 amRNSDirector/PDMR Shareholding
23rd Sep 20141:29 pmRNSHolding(s) in Company
18th Sep 201411:57 amRNSIssue of Equity
11th Sep 20147:00 amRNSHalf Yearly Report
13th Aug 20147:00 amRNSExpands collaboration with Altreos
15th Jul 20147:00 amRNSNew research delivered at AAIC
3rd Jul 20144:58 pmRNSHolding(s) in Company
2nd Jul 20147:00 amRNSHalf Year Pre-Close Update
26th Jun 20147:00 amRNSHuman Abuse and Liability trial contracts won
5th Jun 20147:00 amRNS£1.6m phase III cognitive safety trial
3rd Jun 20147:00 amRNSLaunch of first two products on new platform
28th May 20147:00 amRNSCantab Mobile rolled out in NE Lincolnshire CCG

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.